Clinical Trial Update: The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients [Phase 3]

View source ↗

Summary

Phase 3 trial investigating dapagliflozin plus exenatide in obese insulin-resistant patients with type 2 diabetes; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• EXENATIDE (EXENATIDE)

Snippet

Sponsor: Universitätsklinikum Hamburg-Eppendorf | Conditions: Obesity, Diabetes Mellitus, Type 2 | Phase 3 | Status: TERMINATED